Your browser doesn't support javascript.
loading
Antioxidant Lipid Supplement on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis.
Wan, Sitong; Wu, Wenbin; Zhang, Yan; He, Jian; Wang, Xiaoping; An, Peng; Luo, Junjie; Zhu, Yinhua; Luo, Yongting.
Afiliación
  • Wan S; College of Food Science and Engineering, Gansu Agricultural University, Lanzhou 730070, China.
  • Wu W; Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
  • Zhang Y; Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
  • He J; College of Food Science and Engineering, Gansu Agricultural University, Lanzhou 730070, China.
  • Wang X; National Center of Technology Innovation for Dairy, Hohhot 010110, China.
  • An P; Zhejiang Medicine Co., Ltd., Shaoxing 312366, China.
  • Luo J; Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China.
  • Zhu Y; Food Laboratory of Zhongyuan, Luohe 462300, China.
  • Luo Y; State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Nutrients ; 16(14)2024 Jul 10.
Article en En | MEDLINE | ID: mdl-39064656
ABSTRACT
The efficacy of functional lipids with antioxidant properties in reducing cardiovascular risk has not been consistent. Randomized controlled trials (RCTs) reporting estimates for the effects of antioxidant functional lipid supplementations on cardiometabolic risk factors were searched up to 1 May 2024. Overall, antioxidant lipid supplementations, compared with placebo, had favorable effects on systolic blood pressure (lycopene -1.95 [-3.54, -0.36] mmHg), low-density lipoprotein cholesterol (n6 fatty acid -0.39 [-0.71, -0.06] mmol/L; astaxanthin -0.11 [-0.21, -0.01] mmol/L), high-density lipoprotein cholesterol (n3 fatty acid 0.20 [0.13, 0.27] mmol/L; n6 fatty acid 0.08 [0.01, 0.14] mmol/L; astaxanthin 0.13 [0.05, 0.21] mmol/L), total cholesterol (n6 fatty acid -0.24 [-0.37, -0.11] mmol/L; astaxanthin -0.22 [-0.32, -0.12] mmol/L; beta-carotene -0.13 [-0.23, -0.04] mmol/L), triglyceride (n3 fatty acid -0.37 [-0.47, -0.28] mmol/L; astaxanthin -0.46 [-0.83, -0.10] mmol/L), and fasting blood insulin (astaxanthin -2.66 [-3.98, -1.34] pmol/L). The benefits of antioxidant lipid supplementations appeared to be most evident in blood pressure and blood lipids in participants with different cardiometabolic health statuses. Notably, n9 fatty acid increased triglyceride and hemoglobin A1C in the total population, which increases CVD risk. Antioxidant lipid supplementations ameliorate cardiometabolic risk factors, while their effect may depend on type and cardiometabolic health status. Long-term RCTs are needed to corroborate risk-benefit ratios across different antioxidant functional lipid supplementation settings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Suplementos Dietéticos / Factores de Riesgo de Enfermedad Cardiaca / Lípidos / Antioxidantes Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Nutrients Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Suplementos Dietéticos / Factores de Riesgo de Enfermedad Cardiaca / Lípidos / Antioxidantes Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Nutrients Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza